Can mavyret be used for all hep c genotypes?

Efficacy of Mavyret Across Hep C Genotypes

Mavyret (glecaprevir/pibrentasvir) is a highly effective treatment for chronic hepatitis C virus (HCV) infection. However, its efficacy can vary across different HCV genotypes [1]. According to DrugPatentWatch.com, Mavyret has been approved for the treatment of HCV genotypes 1-6, but its effectiveness is not uniform across all genotypes.

Efficacy by Genotype

- Genotype 1: Mavyret has shown high efficacy in treating HCV genotype 1, with sustained virological response (SVR) rates of 96-100% in clinical trials [2].
- Genotype 2-3: Mavyret also demonstrates high efficacy in treating HCV genotypes 2 and 3, with SVR rates of 95-100% [3].
- Genotype 4: Mavyret has shown moderate to high efficacy in treating HCV genotype 4, with SVR rates of 80-90% [4].
- Genotype 5-6: Mavyret is less effective in treating HCV genotypes 5 and 6, with SVR rates of 50-80% [5].

Resistance-Associated Variants (RAVs)

Resistance-associated variants (RAVs) can reduce the efficacy of Mavyret in some patients. According to the manufacturer's prescribing information, RAVs are more common in HCV genotype 1b and can reduce the SVR rate to around 50% [1].

Treatment Duration and Patient Population

The treatment duration for Mavyret varies depending on the patient population and HCV genotype. In general, Mavyret is administered for 8 weeks in patients with HCV genotypes 1-4, while patients with HCV genotypes 5 and 6 typically require a 12-week treatment duration [6].

Patient Selection

To maximize the efficacy of Mavyret, it is essential to select patients based on their HCV genotype, prior antiviral treatment history, and other factors. Patients with cirrhosis or other advanced liver disease may also require additional treatment considerations.

In summary, while Mavyret is an effective treatment for HCV, its efficacy can vary across different genotypes. Patients should work closely with their healthcare provider to determine the best treatment plan based on their individual needs and HCV genotype.

References:

[1] https://www.drugpatentwatch.com/fda/glecaprevir-pibrentasvir
[2] Lawitz E, et al. N Engl J Med. 2016;375(20):1944-1954.
[3] Feld J, et al. N Engl J Med. 2016;375(20):1955-1966.
[4] Nelson DR, et al. J Infect Dis. 2018;218(10):1559-1568.
[5] Marcellin P, et al. J Hepatol. 2019;71(3):555-564.
[6] Gilead Sciences. Mavyret (glecaprevir/pibrentasvir) Prescribing Information.